RPT-BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris
September 13, 2017 at 18:16 PM EDT
* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis
